Claim verdict
Metabolic
“Setmelanotide is another general-purpose weight-loss GLP-1.”
This verdict applies to the exact claim above. It is not a verdict on the compound overall, a safety guarantee, or a recommendation to use it.
Registry verdict
Misleading — wrong mechanism, wrong population.
Why this verdict
- Setmelanotide is a melanocortin-4 receptor agonist, not a GLP-1; the drug class is different.
- Its approval covers obesity due to specific genetically defined syndromes (such as POMC, PCSK1 or LEPR deficiency and Bardet-Biedl syndrome), confirmed by genetic testing.
- It is not indicated for, and has not been shown to work as, a general obesity treatment.